In addition, they reported that the pharmacological blockade of NLRP3 with the selective inhibitor MCC950, through a decrease in the production of IL-1β, attenuated disease severity counteracting joint inflammation and bone destruction, thus suggesting that NLRP3-induced IL-1β release contributes to shaping and sustaining the immune/inflammatory processes in RA, and, most importantly, that inflammasome could represent a suitable pharmacological target for the management of RA [9]. Here, NLRP3 is linked to rheumatoid arthritis.